… the existing proven delivery technology to the liver, the opportunity to monitor early biomarkers to establish target … in human genetics with a significantly lower chance of developing cardiovascular disease. ProQR intends to advance … 8 th annual Oligonucleotide and Precision Therapeutics (OPT) Congress and at the bi-annual RNA Editing Gordon …
… genetic eye disease, QR-504a for Fuchs endothelial corneal dystrophy.” Business Operations and Program Updates … protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended … with advanced FECD. Currently there are no treatment options available to stop or slow down FECD and disease …
… Fuchs Focus study of QR-504a for Fuchs Endothelial Corneal Dystrophy (FECD) is currently open for enrollment. This study … protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended … with advanced FECD. Currently there are no treatment options available to stop or slow down FECD and disease …
… diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt). ProQR’s presentation at Ophthalmology …
… ProQR Announces Third Quarter 2024 Operating and Financial Results AX-0810 targeting NTCP for … with Eli Lilly , as well as exercise of the underwriter’s option for 1,940,072 additional shares for gross proceeds … totaling approximately $82.1 million. Research and development (R&D) costs were €9.4 million for the quarter …
… received orphan drug designation (ODD) from the FDA and European Medicines Agency (EMA). QR-411 targets the … QR-010 is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… (0.72) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w